EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Targeted Therapies in Neurofibromatosis Type 1

Aimee A Sato iD, Dawn Earl iD, Stephanie E Wallace iD

American Journal of Medical Genetics Part C: Seminars in Medical Genetics · 2025-09 · 199 (3) · 154-160

DOI: 10.1002/ajmg.c.32151 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift American Journal of Medical Genetics Part C: Seminars in Medical Genetics, online erschienen am 18.09.2025. Verfasst von Aimee A Sato und 2 weiteren Autor:innen. Beteiligte Einrichtung: University of Washington, Seattle, Washington, USA. Hauptthemen laut MEDLINE: Neurofibromatosis 1, Molecular Targeted Therapy, Protein Kinase Inhibitors. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 54 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Neurofibromatosis type 1 (NF1) is a progressive multisystem condition that is characterized by a wide range of clinical manifestations and clinical variability. Individuals with NF1 can be significantly impacted by NF1‐related complications, and targeted therapies are emerging. Currently, MEK inhibitors selumetinib and mirdametinib are the only FDA‐approved targeted therapies for NF1‐related symptomatic or progressive, inoperable plexiform neurofibromas. Several additional MEK inhibitors are being investigated in clinical trials for the treatment of plexiform neurofibromas. Additional therapies are currently under investigation for the treatment of malignant peripheral nerve sheath tumors, low‐grade gliomas, skeletal manifestations, cutaneous neurofibromas, and other NF1‐related complications.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neurofibromatosis 1Molecular Targeted TherapyProtein Kinase InhibitorsHumansNeurofibroma, PlexiformNeurofibromin 1Benzimidazoles

Stichwörter der Autor:innen

MEK inhibitorlow‐grade gliomaneurofibromatosis type 1plexiform neurofibromatargeted therapy

Substanzen

Protein Kinase InhibitorsNeurofibromin 1BenzimidazolesAZD 6244

Autor:innen und Institutionen

  • University of Washington, Seattle, Washington, USA.
  • Division of Genetic Medicine, University of Washington (SEW), Seattle Children's Hospital (DE), Seattle, Washington, USA.

ORCID-Profile: Aimee A Sato, Dawn Earl, Stephanie E Wallace

Zitieren

APA

Sato, A. A., Earl, D., & Wallace, S. E. (2025). Targeted Therapies in Neurofibromatosis Type 1. American Journal of Medical Genetics Part C: Seminars in Medical Genetics, 199(3), 154-160. https://doi.org/10.1002/ajmg.c.32151

Vancouver

Sato AA, Earl D, Wallace SE. Targeted Therapies in Neurofibromatosis Type 1. American Journal of Medical Genetics Part C: Seminars in Medical Genetics. 2025;199(3):154-160. doi:10.1002/ajmg.c.32151

BibTeX
@article{Sato2025,
  author = {Sato, Aimee A and Earl, Dawn and Wallace, Stephanie E},
  title = {Targeted Therapies in Neurofibromatosis Type 1},
  journal = {American Journal of Medical Genetics Part C: Seminars in Medical Genetics},
  year = {2025},
  volume = {199},
  number = {3},
  pages = {154--160},
  doi = {10.1002/ajmg.c.32151}
}
Kostenlos starten →